Published in Bioorg Med Chem Lett on April 30, 2012
Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles. Bioorg Med Chem Lett (2012) 0.82
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia (2013) 0.81
Development of inhibitor-directed enzyme prodrug therapy (IDEPT) for prostate cancer. Bioconjug Chem (2014) 0.78
Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities. FEBS J (2015) 0.75
Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer (2004) 9.24
Crystal structure of core streptavidin determined from multiwavelength anomalous diffraction of synchrotron radiation. Proc Natl Acad Sci U S A (1989) 5.57
THE PROPERTIES OF STREPTAVIDIN, A BIOTIN-BINDING PROTEIN PRODUCED BY STREPTOMYCETES. Arch Biochem Biophys (1964) 2.96
Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res (1999) 2.55
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol (2005) 2.55
Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res (1998) 2.38
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res (2009) 2.03
NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov (2005) 1.89
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res (1996) 1.88
Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A (1996) 1.70
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J (2006) 1.55
Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A (2005) 1.49
Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs. Proc Natl Acad Sci U S A (1999) 1.46
Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today (2007) 1.42
Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm (2009) 1.36
Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate (2008) 1.36
Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome (2001) 1.36
Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med (2009) 1.31
Brave new (strept)avidins in biotechnology. Trends Biotechnol (2007) 1.29
Application of avidin-biotin technology to affinity-based separations. J Chromatogr (1990) 1.22
Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology (2001) 1.22
Avidin-biotin technology in targeted therapy. Expert Opin Drug Deliv (2010) 1.20
Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry (2008) 1.17
Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography. Protein Expr Purif (2006) 1.13
A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res (2006) 1.10
Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway. Int J Oncol (2010) 1.09
The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem (2007) 1.08
Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption. Cancer Lett (2010) 1.06
Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res (1998) 1.03
A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorg Med Chem Lett (2010) 1.01
Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. Mol Pharm (2009) 0.95
Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. Acta Crystallogr D Biol Crystallogr (2007) 0.94
In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen. Prostate (2009) 0.93
Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem (2006) 0.93
Trapping of intact, singly-charged, bovine serum albumin ions injected from the atmosphere with a 10-cm diameter, frequency-adjusted linear quadrupole ion trap. J Am Soc Mass Spectrom (2008) 0.90
Optimizing phenylethylphosphonamidates for the inhibition of prostate-specific membrane antigen. Bioorg Med Chem (2005) 0.89
Controlling the expansion into vacuum-the enabling technology for trapping atmosphere-sampled particulate ions. J Am Soc Mass Spectrom (2009) 0.89
Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium. Int J Oncol (2011) 0.89
Simulation of Duty Cycle-Based Trapping and Ejection of Massive Ions Using Linear Digital Quadrupoles: the Enabling Technology for High Resolution Time-of-Flight Mass Spectrometry in the Ultra High Mass Range. Int J Mass Spectrom (2011) 0.88
Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen. Bioorg Med Chem Lett (2011) 0.88
High resolution time-of-flight mass analysis of the entire range of intact singly-charged proteins. Anal Chem (2011) 0.88
Design, synthesis and pharmacological activity of novel enantiomerically pure phosphonic acid-based NAALADase inhibitors. Org Biomol Chem (2007) 0.87
Cell adhesion to streptavidin via RGD-dependent integrins. Eur J Cell Biol (1993) 0.86
Capture and visualization of hydrogen sulfide by a fluorescent probe. Angew Chem Int Ed Engl (2011) 1.57
Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads. Prostate (2012) 1.44
Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate (2008) 1.36
Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med (2009) 1.31
Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem (2004) 1.23
Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry (2008) 1.17
Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography. Protein Expr Purif (2006) 1.13
Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway. Int J Oncol (2010) 1.09
Substrate specificity of prostate-specific membrane antigen. Bioorg Med Chem (2007) 1.09
The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem (2007) 1.08
Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells. Int J Oncol (2012) 1.06
Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption. Cancer Lett (2010) 1.06
A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorg Med Chem Lett (2010) 1.01
Mitochondria-targeted antioxidants protect pancreatic β-cells against oxidative stress and improve insulin secretion in glucotoxicity and glucolipotoxicity. Cell Physiol Biochem (2011) 0.94
In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen. Prostate (2009) 0.93
From AR to c-Met: androgen deprivation leads to a signaling pathway switch in prostate cancer cells. Int J Oncol (2013) 0.92
PSMA-targeted SPECT agents: mode of binding effect on in vitro performance. Prostate (2012) 0.91
A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent. Prostate (2012) 0.91
Trapping of intact, singly-charged, bovine serum albumin ions injected from the atmosphere with a 10-cm diameter, frequency-adjusted linear quadrupole ion trap. J Am Soc Mass Spectrom (2008) 0.90
Controlling the expansion into vacuum-the enabling technology for trapping atmosphere-sampled particulate ions. J Am Soc Mass Spectrom (2009) 0.89
Optimizing phenylethylphosphonamidates for the inhibition of prostate-specific membrane antigen. Bioorg Med Chem (2005) 0.89
Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium. Int J Oncol (2011) 0.89
Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs. Bioorg Med Chem Lett (2007) 0.88
Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen. Bioorg Med Chem Lett (2011) 0.88
Simulation of Duty Cycle-Based Trapping and Ejection of Massive Ions Using Linear Digital Quadrupoles: the Enabling Technology for High Resolution Time-of-Flight Mass Spectrometry in the Ultra High Mass Range. Int J Mass Spectrom (2011) 0.88
High resolution time-of-flight mass analysis of the entire range of intact singly-charged proteins. Anal Chem (2011) 0.88
Cross-talk-free dual-color fluorescence cross-correlation spectroscopy for the study of enzyme activity. Anal Chem (2010) 0.84
Flow cytometric detection of prostate tumor cells using chemoaffinity labels. Prostate (2011) 0.84
Stereoselective inhibition of glutamate carboxypeptidase by organophosphorus derivatives of glutamic acid. Bioorg Med Chem (2004) 0.82
Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles. Bioorg Med Chem Lett (2012) 0.82
Increasing the Trapping Mass Range to m/z = 10(9)-A Major Step Toward High Resolution Mass Analysis of Intact RNA, DNA and Viruses. Int J Mass Spectrom (2012) 0.81
Limitation of time-of-flight resolution in the ultra high mass range. Anal Chem (2011) 0.80
Double resonance ejection in a micro ion trap mass spectrometer. Rapid Commun Mass Spectrom (2002) 0.80
Development of inhibitor-directed enzyme prodrug therapy (IDEPT) for prostate cancer. Bioconjug Chem (2014) 0.78
The hydrazide/hydrazone click reaction as a biomolecule labeling strategy for M(CO)3 (M = Re, (99m)Tc) radiopharmaceuticals. Chem Commun (Camb) (2011) 0.78
Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen. Bioorg Med Chem Lett (2007) 0.78
Endoscopic resection of gastric neoplasm in solid-organ transplant recipients. Transplantation (2014) 0.77
High-performance liquid chromatography method for detecting prostate-specific membrane antigen activity. Anal Biochem (2002) 0.77
Integration of microfluidic chip with biomimetic hydrogel for 3D controlling and monitoring of cell alignment and migration. J Biomed Mater Res A (2013) 0.75
N-substituted glutamyl sulfonamides as inhibitors of glutamate carboxypeptidase II (GCP2). Chem Biol Drug Des (2011) 0.75
Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells. Prostate (2014) 0.75
Analysis of volatile organic compounds in air with a micro ion trap mass analyzer. Anal Chem (2003) 0.75
High-resolution ultra-high mass spectrometry: increasing the m/z range of protein analysis. Proteomics (2012) 0.75
Sample pressure effects in a micro ion trap mass spectrometer. Rapid Commun Mass Spectrom (2004) 0.75
Rationally designed sulfamides as glutamate carboxypeptidase II inhibitors. Chem Biol Drug Des (2013) 0.75
Development of MS(n) in digitally operated linear ion guides. Anal Chem (2014) 0.75
High-pressure ion trap mass spectrometry. Rapid Commun Mass Spectrom (2004) 0.75
Toward reducing uncertainty in Fluorescence Recovery After Photobleaching. Conf Proc IEEE Eng Med Biol Soc (2013) 0.75
MALDI of individual biomolecule-containing airborne particles in an ion trap mass spectrometer. Anal Chem (2005) 0.75
Detection of chemical warfare-related species on complex aerosol particles deposited on surfaces using an ion trap-based aerosol mass spectrometer. Anal Chem (2007) 0.75
GeneNetFinder2: Improved Inference of Dynamic Gene Regulatory Relations with Multiple Regulators. IEEE/ACM Trans Comput Biol Bioinform (2016) 0.75
Liquid-phase sample preparation method for real-time monitoring of airborne asbestos fibers by dual-mode high-throughput microscopy. Conf Proc IEEE Eng Med Biol Soc (2013) 0.75